Cargando…

European medicines agency guideline for biological medicinal products: a further step for a safe use of biosimilars

Detalles Bibliográficos
Autores principales:	Agostini, Carlo, Canonica, Giorgio Walter, Maggi, Enrico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4432880/ https://www.ncbi.nlm.nih.gov/pubmed/25983659 http://dx.doi.org/10.1186/s12948-015-0010-3

Ejemplares similares

Review: UK medicines likely to be affected by the proposed European Medicines Agency’s guidelines on phthalates
por: Jamieson, Lisa, et al.
Publicado: (2015)

Overview of the European Medicines Agency's Development of Product‐Specific Bioequivalence Guidelines
por: Sullivan, Jane O', et al.
Publicado: (2018)

Preparing Europe for future health threats and crises ─ the European Medicines Agency; ensuring safe and effective medicines and medical devices
por: Cooke, Emer
Publicado: (2022)

Psychopharmacology at the era of EMEA (European Medicines Agency)
por: Pestana, Luis Camara, et al.
Publicado: (2010)

A bacteriophage journey at the European Medicines Agency
por: Debarbieux, Laurent, et al.
Publicado: (2015)

The European Medicines Agency's approval of new medicines for type 2 diabetes
por: Blind, Eberhard, et al.
Publicado: (2018)

Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?
por: Varricchi, Gilda, et al.
Publicado: (2017)

The Iterative Development of Medicines Through the European Medicine Agency's Adaptive Pathway Approach
por: Nicotera, Giuseppe, et al.
Publicado: (2019)

The Present and Future of Allergen Immunotherapy in Personalized Medicine
por: Ridolo, Erminia, et al.
Publicado: (2022)

Informing Patients about Biosimilar Medicines: The Role of European Patient Associations
por: Vandenplas, Yannick, et al.
Publicado: (2021)

Stratified medicine in practice: review of predictive biomarkers in European Medicines Agency (EMA) indications
por: Malottki, Kinga, et al.
Publicado: (2011)

Stratified medicine in European Medicines Agency licensing: a systematic review of predictive biomarkers
por: Malottki, Kinga, et al.
Publicado: (2014)

Biomarker and Companion Diagnostics—A Review of Medicinal Products Approved by the European Medicines Agency
por: Orellana García, Laura Patricia, et al.
Publicado: (2021)

Overview of the European Medicines Agency's Experience With Biowaivers in Centralized Applications
por: Lenić, Ines, et al.
Publicado: (2019)

The pre‐ and post‐authorisation data published by the European medicines agency on the use of biologics during pregnancy and lactation
por: Ghalandari, N., et al.
Publicado: (2020)

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies
por: Bloem, Lourens T., et al.
Publicado: (2021)

Biosimilar medicines and cost-effectiveness
por: Simoens, Steven
Publicado: (2011)

PReS13-SPK-1408: New EU scientific guidelines for JIA, SLE and GIOP from the European Medicines Agency
por: Vesely, R
Publicado: (2013)

Optimization and Validation of a Chromatographic Method for the Quantification of Isoniazid in Urine of Tuberculosis Patients According to the European Medicines Agency Guideline
por: Mishra, Pooja, et al.
Publicado: (2018)

Biomarker Qualification at the European Medicines Agency: A Look Under the Hood
por: Berman, Steven, et al.
Publicado: (2022)

Biosimilar medicines: creating sustainable competition in an era of a new patent cliff in biological medicines
por: Van Baelen, Maarten
Publicado: (2015)

Mobility endpoints in marketing authorisation of drugs: what gets the European medicines agency moving?
por: Jaeger, Simon U, et al.
Publicado: (2022)

A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment?
por: Allen, Nicola, et al.
Publicado: (2017)

Improving Risk Assessment in the European Food Safety Authority: Lessons From the European Medicines Agency
por: Chatzopoulou, Sevasti, et al.
Publicado: (2020)

European Medicines Agency Conflicts With the European Food Safety Authority (EFSA) on Bisphenol A Regulation
por: Zoeller, R Thomas, et al.
Publicado: (2023)

Access to regulatory data from the European Medicines Agency: the times they are a-changing
por: Wieseler, Beate, et al.
Publicado: (2012)

The European Medicines Agency’s scientific opinion on oral fexinidazole for human African trypanosomiasis
por: Pelfrene, Eric, et al.
Publicado: (2019)

Regulatory Science to 2025: An Analysis of Stakeholder Responses to the European Medicines Agency's Strategy
por: Hines, Philip A., et al.
Publicado: (2020)

Extension of the European Medicines Agency (EMA) approval of trifluridine/tipiracil for gastric cancer
por: Alsina, Maria, et al.
Publicado: (2019)

The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines
por: Cavaleri, Marco, et al.
Publicado: (2021)

Contribution of Real‐World Evidence in European Medicines Agency's Regulatory Decision Making
por: Bakker, Elisabeth, et al.
Publicado: (2022)

Emerging Insights into European Markets of Biologics, Including Biosimilars
por: Simoens, Steven, et al.
Publicado: (2022)

AIT (allergen immunotherapy): a model for the “precision medicine”
por: Passalacqua, Giovanni, et al.
Publicado: (2015)

Pharmacovigilance and the Italian Medicines Agency
por: Pimpinella, Giuseppe, et al.
Publicado: (2013)

Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis
por: Vandenplas, Yannick, et al.
Publicado: (2021)

Nanomedicine and Immunotherapy: A Step Further towards Precision Medicine for Glioblastoma
por: Šamec, Neja, et al.
Publicado: (2020)

Use of real-world evidence in postmarketing medicines regulation in the European Union: a systematic assessment of European Medicines Agency referrals 2013–2017
por: Brown, Jeremy Philip, et al.
Publicado: (2019)

The contributions of the European Medicines Agency and its pediatric committee to the fight against childhood leukemia
por: Rose, Klaus, et al.
Publicado: (2015)

The SSAI fully supports the suspension of hydroxyethyl‐starch solutions commissioned by the European Medicines Agency
por: Laake, J. H., et al.
Publicado: (2018)

The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer
por: Michaleas, S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kas2nlihsfail1q8d8vb1u2nsm